Pharmacology
- 27 topics
- 1,274 questions
- Library, from GHS 83.33 a month
Topics
-
Adrenergic transmission and drugs
- Identify pre- and post-junctional sites for drug action: α-methyltyrosine, reserpine, neuron-blocking drugs (guanethidine), α₂-autoreceptors, uptake inhibitors (cocaine, tricyclic antidepressants), and MAO and COMT inhibitors.
- Describe noradrenaline synthesis (tyrosine hydroxylase as the rate-limiting step), vesicular storage (VMAT), release and inactivation (uptake 1/NET, uptake 2, MAO, COMT).
- Relate receptor selectivity to representative agonists (adrenaline, noradrenaline, isoprenaline, phenylephrine, clonidine, dobutamine, salbutamol) and antagonists (prazosin, phentolamine, propranolol, atenolol, labetalol) at an introductory level.
- Classify adrenoceptors (α₁, α₂, β₁, β₂, β₃) by location, G-protein coupling, second messenger and response.
- Explain false transmitters (methyldopa → α-methylnoradrenaline) and indirectly acting sympathomimetic amines (tyramine, amphetamine, ephedrine), including the tyramine–MAOI interaction.
-
Agonists, antagonists and types of antagonism
- Classify antagonism: reversible competitive, irreversible (non-equilibrium) competitive, non-competitive, allosteric, chemical, pharmacokinetic and physiological (functional), with an example of each.
- Explain the behaviour of a partial agonist given alone and in the presence of a full agonist.
- Predict the effect of each type of antagonist on an agonist concentration–response curve (parallel rightward shift versus depression of the maximum).
-
Chemotherapy of common haematological malignancies
-
Cholinergic transmission and drugs
- Identify the sites for drug action at the cholinergic synapse with an example drug for each: choline uptake (hemicholinium), vesicular storage (vesamicol), release (botulinum toxin), hydrolysis (reversible and irreversible anticholinesterases) and receptors.
- Classify muscarinic receptors (M₁–M₅) by location, G-protein coupling, effector mechanism and function.
- Describe organophosphate poisoning and its management with atropine and pralidoxime.
- Describe muscarinic agonists (acetylcholine, methacholine, carbachol, bethanechol, pilocarpine): effects and uses.
- Describe the synthesis (choline acetyltransferase), vesicular storage, release and hydrolysis (acetylcholinesterase, butyrylcholinesterase) of acetylcholine.
- Describe muscarinic antagonists (atropine, hyoscine, ipratropium, tropicamide, oxybutynin): effects, uses and adverse effects; recognise anticholinergic toxicity.
-
Drug distribution
- Define apparent volume of distribution, calculate it (Vd = dose / C₀) and interpret large and small values.
- Describe redistribution as a determinant of the duration of action (e.g. thiopental).
- Describe body fluid compartments and the factors that determine drug distribution: blood flow, lipid solubility, plasma-protein and tissue binding, and barriers (blood–brain barrier, placenta).
- Explain the clinical relevance of plasma-protein binding (albumin, α₁-acid glycoprotein) and of displacement interactions.
-
Drug excretion
- Define renal clearance and relate it to glomerular filtration rate.
- Describe renal excretion: glomerular filtration, active tubular secretion and passive tubular reabsorption; explain the effect of urinary pH (e.g. urinary alkalinisation in salicylate poisoning).
- Describe biliary excretion and enterohepatic circulation, and minor routes (lungs, breast milk).
-
Drug interactions
- Predict clinically important interactions from their mechanism (e.g. enzyme inducers with oral contraceptives, CYP inhibitors with warfarin, probenecid with penicillin).
- Classify drug interactions as pharmaceutical, pharmacokinetic (absorption, distribution, metabolism, excretion) or pharmacodynamic (additive, synergistic, antagonistic).
-
Drug metabolism (biotransformation)
- Explain the time course and consequences of enzyme induction and inhibition.
- Describe phase I (oxidation, reduction, hydrolysis) and phase II (glucuronidation, sulfation, acetylation, glutathione conjugation, methylation) reactions and the properties of their products.
- Outline the effects of genetics (acetylator status, CYP2D6 polymorphism), age and liver disease on drug metabolism.
- Explain the role of the cytochrome P450 system (CYP3A4, 2D6, 2C9, 2C19, 1A2) and name common enzyme inducers and inhibitors.
- Describe prodrugs, and active and toxic metabolites (e.g. paracetamol and NAPQI).
-
Drug permeation and absorption
- Explain the factors affecting oral absorption; define bioavailability, bioequivalence and first-pass metabolism.
- Apply the Henderson–Hasselbalch equation to predict the ionisation of weak acids and bases and explain ion trapping.
- Compare the routes of drug administration (oral, sublingual, rectal, intravenous, intramuscular, subcutaneous, inhalational, topical, transdermal): advantages and limitations.
- Describe the mechanisms by which drugs cross membranes: passive diffusion, aqueous pores, carrier-mediated transport (SLC and ABC transporters, including P-glycoprotein) and endocytosis.
-
Drug therapy in kidney disease
-
Ganglionic transmission and ganglion-blocking drugs
- Describe ganglion stimulants (nicotine) and blockers (hexamethonium, trimetaphan, mecamylamine), and predict their effects on each organ from its dominant autonomic tone.
- Describe nicotinic (NN) transmission in autonomic ganglia.
-
History and scope of pharmacology
- Distinguish pharmacology from related disciplines (pharmaceutics, pharmacognosy, medicinal chemistry, clinical pharmacy).
- Define pharmacology and distinguish its branches: pharmacodynamics, pharmacokinetics, pharmacotherapeutics, toxicology and pharmacogenomics.
- Outline the major milestones in the history of pharmacology, from materia medica and the isolation of active plant principles to the receptor concept (Langley, Ehrlich) and modern biologics.
-
Integrative autonomic pharmacology and revision
- Predict the net response to autonomic drugs in organs with dual innervation, including baroreceptor reflex responses (e.g. reflex bradycardia with phenylephrine; adrenaline reversal by α-blockade).
- Solve problem-based cases that integrate pharmacodynamic, pharmacokinetic and autonomic principles.
-
Non-adrenergic, non-cholinergic (NANC) and purinergic transmission
- Relate purinergic pharmacology to drugs in use: methylxanthines (caffeine, theophylline), adenosine, dipyridamole and P2Y₁₂ antagonists (clopidogrel).
- Describe nitric oxide as a NANC transmitter (e.g. penile erection, gastrointestinal relaxation) and link it to PDE5 inhibitors.
- Describe purinergic signalling: release and inactivation of ATP and adenosine; P1 (A₁, A₂A, A₂B, A₃) and P2 (P2X ionotropic, P2Y metabotropic) receptors.
- Define NANC transmission and co-transmission; give examples of NANC mediators (ATP, adenosine, nitric oxide, VIP, neuropeptide Y, substance P, CGRP) and the tissues in which they act.
-
Organisation of the efferent nervous system
- Describe the effects of sympathetic and parasympathetic activation on the major effector organs (eye, heart, blood vessels, bronchi, gut, bladder, glands) and the concept of dominant tone.
- Outline the steps of chemical neurotransmission, Dale's principle, co-transmission and presynaptic modulation.
- Compare the somatic efferent, autonomic (sympathetic and parasympathetic) and enteric nervous systems: anatomy, transmitters and receptors at each junction.
-
Overview of drug discovery, development and regulation
- Describe the role of pharmacovigilance and of the national regulatory authority (Food and Drugs Authority, Ghana) in approving and monitoring medicines.
- Outline the stages of drug development: discovery, preclinical testing, clinical trial phases I–IV and post-marketing surveillance.
-
Pharmacology of Diuretic Agents
-
Quantitative analysis of antagonism and radioligand binding
- Calculate dose ratio, KB or pA₂ from experimental data.
- Describe saturation radioligand binding: total, non-specific and specific binding; derive Kd and Bmax; explain how non-specific binding is measured and why it is subtracted.
- Define dose ratio and state the Schild equation (r – 1 = [B]/KB).
- Describe competition binding experiments (IC₅₀) and the conversion of IC₅₀ to Ki (Cheng–Prusoff relationship).
- Construct a Schild plot, determine pA₂ and interpret a slope of unity as evidence of simple competitive antagonism.
-
Quantitative pharmacokinetics and dosing
- Define clearance, elimination rate constant, half-life (t½ = 0.693 × Vd / CL) and area under the curve.
- Describe the principles of therapeutic drug monitoring and the significance of a narrow therapeutic index.
- Distinguish first-order from zero-order (saturation) kinetics, with examples (ethanol, phenytoin, high-dose aspirin).
- Calculate loading and maintenance doses from Vd, CL, target concentration, dosing interval and bioavailability.
- Explain steady state, accumulation and the time to reach steady state (about 4–5 half-lives).
- Interpret plasma concentration–time curves for an intravenous bolus, an oral dose and a constant infusion using a one-compartment model.
-
Receptor families and second-messenger effector systems
- Describe the four receptor superfamilies (ligand-gated ion channels, G protein-coupled receptors, kinase-linked receptors, nuclear receptors): structure, time scale of response and a prototype example of each.
- Explain the G-protein cycle and the main effector pathways: Gs/Gi–adenylyl cyclase–cAMP–protein kinase A; Gq–phospholipase C–IP₃/DAG–Ca²⁺–protein kinase C; direct regulation of ion channels.
- Describe the second messengers (cAMP, cGMP, IP₅, DAG, Ca²⁺, nitric oxide) and explain signal amplification.
-
Receptor regulation, desensitisation and tolerance
- Define and distinguish desensitisation, tachyphylaxis and tolerance.
- Describe the mechanisms of desensitisation: receptor uncoupling (phosphorylation by GRKs, PKA, PKC; β-arrestin binding), sequestration/internalisation, down-regulation and degradation, mediator depletion, increased drug metabolism and physiological adaptation.
- Explain receptor up-regulation and supersensitivity (e.g. rebound after abrupt β-blocker withdrawal) and their clinical implications.
- Distinguish homologous from heterologous desensitisation, with examples.
-
Relation between binding and response: affinity and efficacy
- Explain spare receptors (receptor reserve) and their effect on agonist potency and on the action of irreversible antagonists.
- Construct and interpret graded concentration–response curves (arithmetic and log scale) and quantal dose–response curves (ED₅₀, TD₅₀, LD₅₀, therapeutic index, margin of safety).
- Distinguish full agonists, partial agonists, inverse agonists and neutral antagonists; explain constitutive receptor activity.
- Apply the law of mass action and occupancy theory (Hill–Langmuir equation) to relate drug concentration to receptor occupancy.
- Define and distinguish affinity (KA/Kd), efficacy (intrinsic activity), potency (EC₅₀) and maximal effect (Emax).
-
Somatic efferent transmission: the neuromuscular junction
- Describe transmission at the skeletal neuromuscular junction (NM receptors, end-plate potential).
- Distinguish non-depolarising (tubocurarine, atracurium, rocuronium) from depolarising (suxamethonium) neuromuscular blockers, including phase I and phase II block and reversal (anticholinesterases, sugammadex).
-
Sources, nature and nomenclature of drugs
- Identify the sources of drugs (plant, animal, mineral, microbial, synthetic and semi-synthetic, biotechnological) with at least one example of each, including medicines derived from plants used in Ghanaian traditional medicine.
- Describe the physical nature of drugs (state, molecular size, reactivity) and explain the significance of chirality and enantiomers for drug action.
- Apply drug nomenclature correctly: chemical name, code name, generic (International Non-proprietary Name) and proprietary (brand) name; explain why generic prescribing is preferred.
- Define drug, medicine, prodrug and placebo.
-
Targets of drug action and drug–receptor interaction
- Name the four main classes of protein target (receptors, ion channels, enzymes, carriers/transporters) and give an example drug acting on each.
- Explain drug specificity, selectivity, structure–activity relationships and stereoselectivity.
- Distinguish drugs acting on specific targets from those acting by non-specific physicochemical mechanisms (e.g. antacids, osmotic diuretics, chelating agents).
- Describe the forces involved in drug–receptor interaction (ionic, hydrogen, van der Waals, hydrophobic, covalent) and relate bond type to reversibility and duration of action.
-
The principle and pharmacology of coagulant and anticoagulant therapy
-
Across the subject